Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

Hyperlipidemia Clinical Trial

Official title:

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01327014
• Other study ID #: WPU-201
• Status: Completed
• Phase: Phase 2
• First received: March 30, 2011
• Last updated: July 22, 2014
• Start date: April 2011
• Est. completion date: December 2012

Study information

• Verified date: July 2014
• Source: Beijing Peking University WBL Biotech Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate the efficacy of XueZhiKang to improve plasma lipid profile, as compared to placebo, in outpatients with hyperlipidemia.

Description:

This is a multi-center, double-blind, randomized, placebo-controlled, parallel group study to be conducted in approximately 120 patients with hyperlipidemia in approximately 10 sites in US and China. Patients who satisfy the entry criteria at screening visit will have a 4-week Therapeutic Lifestyle Changes (TLC) diet control period during which all lipid-lowering medications will be discontinued. After the 4-week diet control period, eligible patients will be randomized to one of three treatment groups. The treatment period will last for 12-weeks. Patients will have blood samples collected at 5 time points (screening, baseline, Week 4, Week 8, and Week 12).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 116
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients who have been diagnosed with hyperlipidemia as defined by fasting levels of TC = 240 mg/dl and LDL-C = 160 mg/dl but < 190 mg/dl and TG < 400 mg/dl.

2. Patients with a 10-year coronary heart disease risk Framingham Point Score of < 10%.

3. Male or female patients, of any race, at least 18 years of age.

4. Female patients must be postmenopausal as defined by no menstruation for at least 12 months, or surgically sterilized for at least three months prior to beginning the study, or have a negative pregnancy test and agree to avoid pregnancy during the study and one month after the end of the study by using two reliable methods of contraception.

5. Patients must have been informed of all aspects of the study and signed an informed consent form before any study-related activities.

6. Patients must be willing to follow the TLC diet.

7. BMI < 36 kg/m2.

8. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

1. Patients with myocardial infarction, stroke, transient ischemic attack, cardiovascular surgery or major operations within 6 months prior to screening visit.

2. Patients with percutaneous coronary intervention within 3 months.

3. Patients who have been taken lipid-lowering medications including statins or XZK during the 4 weeks prior to screening visit.

4. Patients with uncontrolled hypertension at the screening visit. Patients on stable antihypertensive medication may be enrolled provided that the medications and dosage remain stable throughout the study.

5. Patients who are taking anticoagulants except aspirin at < 325 mg/day.

6. Patients with liver dysfunction as indicated by a serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) level of > 1.5-times of upper limit of normal (ULN) range, or clinical symptoms.

7. Patients with elevated creatine phosphokinase level (above Upper Limit of Normal range).

8. Patients with renal dysfunction as indicated by a serum creatinine level above ULN range, or clinical symptoms.

9. Patients with gastric or peptic ulcer within 3 months prior to screening visit.

10. Patients with uncontrolled diabetes mellitus as defined by a HbA1c level of > 7.0%.

11. Patients with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, or primary biliary cirrhosis. Patients on thyroid replacement therapy at stable doses may be enrolled if clinically euthyroid.

12. Patients with clinically relevant illness within 4 weeks prior to the screening visit that may interfere with the conduct of this study.

13. Patients with a history of alcohol or narcotic substance abuse within two years prior to screening visit.

14. Patients with hypersensitivity to lipid-lowering agents.

15. Patients who have taken another investigational drug within 4 weeks prior to screening visit.

16. Patients with uncontrolled metabolic or endocrine disease knowing to influence lipid values.

17. Patients who are known to be HIV positive.

18. Patients who have a history or presence of active malignancy (other than non-melanoma skin cancer) or clinically significant psychiatric, neurological, respiratory, hematological, or other conditions that in the opinion of investigators might interfere with or contraindicate participation of the patients in this study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hyperlipidemia
• Hyperlipidemias

Intervention

Drug:
• XueZhiKang (XZK), a botanic product with multiple components
4 capsules of study drug twice a day for 12 weeks.
• Placebo
4 capsules twice a day for 12 weeks.

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing
China	Second Xiangya Hospital of Central-South Univ	Changsha	Hunan
China	Shanghai First People's Hospital	Shanghai	Shanghai
China	Shanghai Ruijin Hospital	Shanghai	Shanghai
China	Wuhan Union Hospital	Wuhan	Hubei
United States	Robert Karns, MD A Medical Corporation	Beverly Hills	California
United States	Eli M Roth, MD	Cincinnati	Ohio
United States	Osvaldo Brusco, MD	Corpus Christi	Texas
United States	Jellinger and Lerman, MD	Hollywood	Florida
United States	Clinical Trial Network	Houston	Texas
United States	Department of Internal Medicine, University of Kansas Medical Center	Kansas City	Kansas
United States	Harold E Bays, MD	Louisville	Kentucky
United States	Cardiovascular Medical Associates	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Peking University WBL Biotech Co., Ltd.

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean percentage change from baseline at week 12 (or the last assessment) on serum low-density lipoprotein cholesterol (LDL-C) level.		Screening, Baseline, Week 4, Week 6, and Week 12	No
Secondary	Mean percentage change from baseline at week 12 (or the last assessment on serum total cholesterol (TC) level.		Screening, Baseline, Week 4, Week 6, and Week 12	No
Secondary	Mean percentage change from baseline at week 12 (or the last assessment) on serum high-density lipoprotein cholesterol (HDL-C) level		Screening, Baseline, Week 4, Week 6, and Week 12	No
Secondary	Mean percentage change from baseline at week 12 (or the last assessment) on serum triglyceride (TG) level.		Screening, Baseline, Week 4, Week 6, and Week 12	No
Secondary	Mean percentage change from baseline at week 12 (or the last assessment) on serum non-HDL cholesterol level.		Screening, Baseline, Week 4, Week 6, and Week 12	No
Secondary	Mean percentage change from baseline at week 12 (or the last assessment) on serum apolipoprotein A-I (Apo A-I) and serum apolipoprotein-B (Apo-B) and the Apo-B/Apo A-I ratio.		Screening, Baseline, Week 4, Week 6, and Week 12	No
Secondary	Mean percentage change from baseline at week 12 (or the last assessment) on the serum TC/HDL-C ratio.		Screening, Baseline, Week 4, Week 6, and Week 12	No
Secondary	Percentage of patients who show a LDL-C level of <130 mg/dl or <100 mg/dl at end of the study.		Screening, Baseline, Week 4, Week 6, and Week 12	No
Secondary	Safety will be assessed by the incidence of adverse events (AEs), discontinuation due to the AEs, clinically relevant changes on laboratory test results, vital signs, physical examinations, and 12-lead electrocardiograms (ECG).		Screening, Baseline, Week 4, Week 6, and Week 12; ECG and Physical exam only at Screening and Week 12.	Yes